Participants were randomized to @ of @ treatment sequences in which they received @ of @ treatments : evacetrapib @ mg daily for @ days ( supratherapeutic dose ) , moxifloxacin @ mg for @ day ( positive control ) , or placebo for @ days in each of the @ separate treatment periods .